^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

    Excerpt:
    ...Subjects must have tested positive for FLT3-ITD and/or other FLT3 activating mutations 5....
    Trial ID:
    NCT02283177
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

    Excerpt:
    ...- Patients must have tested positive for FLT3-ITD and /or other FLT3 activating mutations within < 60 days of the screening period....
    Trial ID:
    NCT01522469
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML

    Published date:
    05/26/2022
    Excerpt:
    Crenolanib maintenance therapy was offered...33 (75%) pts had FLT3-ITD, 8 (18%) had TKD, and 3 (7%) had ITD and TKD mutations. 11 pts had concomitant NPM1/DNMT3A mutations...11 pts had concomitant NPM1/DNMT3A mutations...CRc rates > 80% were noted in pts ≤ 60 yo, FLT3-ITD mutations, concomitant FLT3/DMT3A/NPM1 mutations...Long-term outcomes of a phase 2 trial of crenolanib combined with 7+3 induction and consolidation in adults with newly diagnosed FLT3 mutant AML demonstrate high response rates (CRc 86%).
    Secondary therapy:
    cytarabine + daunorubicin; cytarabine
    DOI:
    10.1200/JCO.2022.40.16_suppl.7007
    Trial ID:
    NCT02283177